Role of antihypertensive treatment in heart failure prevention;Papel del tratamiento antihipertensivo en la prevención de la insuficiencia cardiaca

Revista Espanola de Cardiologia Suplementos

Volumn 7, Issue F, 2007, Pages

  Roig, Eulàlia ^a   Coca, Antonio ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiotensin II receptor antagonist; Angiotensin converting enzyme inhibitor; Beta blocker; Heart failure; Hypertension; Ventricular hypertrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LISINOPRIL; METOPROLOL; NEBIVOLOL; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; RESERPINE; SPIRONOLACTONE; TORASEMIDE; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIASTOLIC HEART FAILURE; DISEASE COURSE; FLUID RETENTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MEDICAL SOCIETY; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SECONDARY PREVENTION; SINUS RHYTHM; SURVIVAL; SYSTOLIC HYPERTENSION;

EID: 38149094012     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(07)75253-6     Document Type: Article

References (64)

1. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
3. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139-85.
4. Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, et al. The 2004 Canadian recommendations for the management of hypertension: Part II-Therapy. Can J Cardiol. 2004;20:41-54.
5. Sociedad Española de Hipertensión. Guía española de hipertensión arterial 2005. Hipertensión. 2005;22 Suppl 2:s1-s84.
6. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Meaton J, et al. Blood Pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure. Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;355:765-74.
7. Multiple Risk Factor Intervention Trial. Mortality after 10 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-28.
8. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population Data. Arch Intern Med. 1993;153:598-615.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.
10. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-92.
11. Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tomás L, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol. 2000;53:66-90.
12. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on mortality in hypertension III. Influence of age, diastolic blood pressure, and prior cardiovascular disease; further analysis of side effects. Circulation. 1972;45:991-1004.
13. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-71.
14. Amery A, Brixko P, Clement D, De Schaepdryver A, Fagard R, Forte J, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;1:1349-54.
15. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145-51.
16. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet. 1991;338:1281-5.
17. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-12.
18. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-6.
19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
20. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al, for the Systolic Hypertension in Europe (Syst-eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-64.
21. Liu L, Wang JG, Gong L, Liu G, Staessen J, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-9.
22. Somes GW, Pahor M, Shorr IR, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med. 1999;159:2004-9.
23. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-76.
24. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-35.
25. The ALLHAT investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981-97.
26. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
27. Hunt S, and writing committee members. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic Heart failure in the adult. A report of the American College of Cardiology/American Heart Association task force on practice guidelines, 2005.
28. M Maurer, D Spevack, D Burkhoff, I Kronzon. Diastolic dysfunction. Can it be diagnosed by doppler echocardiography? J Am Coll Cardiol. 2004;44:1543-9.
29. Aurigemma G, Gaasch W. Diastolic heart failure. N Engl J Med. 2004;351:1097-105.
30. Sacha R, Tu J, Lee D, Austin P, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction I a population-based study. N Engl J Med. 2006;355:260-9.
31. Varela-Roman A, González-Juantey JR, Basante P, Trillo R, García-Seara J, Martínez-Sande J, et al. Clinical characteristics and prognosis of hospitalized inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002;88:249-54.
32. Wu E, Yu C. Management of diastolic heart failure: a practical review of pathophysiology and treatment trial data. Int J Clin Pract. 2005;59:1239-46.
33. Cleland J, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, on behalf of PEP-Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45.
34. López B, Querejeta R, González A, Sánchez E, Lerman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-20.
35. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006;27:2387-93.
36. Aronow W, Ahn C, Kronzon I. Effect of propranolol vs no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure and left ventricular ejection fraction ≥ 40% treated with diuretics plus ACEI. Am J Cardiol. 1997;80:207-9.
37. Setaro J, Zaret B, Schulman D, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66:981-6.
38. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM overall programme. Lancet. 2003;362:759-66.
39. Arias M, García-Rio F, Alonso-Fernández A, Mediano O, Martínez I, Villamar J. Obstructive sleep apnea syndrome affects left ventricular diastolic function. Effects of nasal continuous positive airway pressure in men. Circulation. 2005;112:375-83.
40. Flather M, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al, for the ACE-inhibitor myocardial infarction Collaborative Group. Lancet. 2000;355:1575-81.
41. The CONSENSUS trial Study Group. Effects of enalapril on mortality in severe heart failure. N Engl J Med. 1987;316:1429-31.
42. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
43. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91.
44. Pfeffer MA, Braunwald E, Moye LA. Basta L, Brown EJ Jr, Cuddy TE, et al for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-77.
45. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1997;342:821-8.
46. Kober L, Top-Pedersen C, Carlsen J, Bagger H, Eliasen P, Lyngborg K, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-6.
47. Packer M, Bristow M, Chon J, Colucci W, Fowler M, Gilbert E, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55.
48. Packer M, Coats A, Fowler M, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. COPERNICUS trial. N Engl J Med. 2001;344:1651-8.
49. CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
50. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-7.
51. Flather M, Shibata M, Coats A, Van Veldhuisen D, Parkhomenko A, Borbola J, et al. FASTRACK Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
52. Pfeffer MA, McMurray JJ, Velázquez E, Rouleau JL, Kober L, Maggioni A, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 2003;349:1893-906.
53. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang Y, et al, for the Val-Heft Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-Heft echocardiographic study. J Am Coll Cardiol. 2002;40:970-8.
54. Cosín J, Díez J; TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-13
55. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-11.
56. Pitt B, Remme WJ, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
57. Gheorghiade M, Niazi I, Oyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopresin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial. Circulation. 2003;107:2690-6.
58. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-33.
59. Adams K, Gheorghiae M, Urestky B, Patterson J, Schwartz T, Young J. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946-53.
60. Cohn J, Archivald D, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-52.
61. Cohn J, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril, hydralazine plus isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-10.
62. Taylor A, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al, for the African-American Heart Failure Trial Investigators. Combination of isosobide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57.
63. Cohn J, Ziesche S, Smith R, Anand I, Dinkman B, Loeb H, et al. Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96:856-63.
64. Thackray S, Witte K, Clark A, Cleland JG. Clinical trials update: Optime,-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000;2:209-12.